ANTHERA PHARMACEUTICALS
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2004-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.anthera.com
Clinical Trials
27
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
RESULT: Reliable, Emergent Solution Using Liprotamase Treatment
- Conditions
- Exocrine Pancreatic InsufficiencyCystic Fibrosis
- Interventions
- Drug: porcine PERT
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT03051490
- Locations
- 🇺🇸
Investigator Site 139, Little Rock, Arkansas, United States
🇺🇸Investigator Site #123, Long Beach, California, United States
🇺🇸Investigator Site 107, Los Angeles, California, United States
EASY: Extended Access to Sollpura Over Years
- Conditions
- Exocrine Pancreatic InsufficiencyCystic Fibrosis
- Interventions
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT02823964
- Locations
- 🇺🇸
Investigator Site 114, Aurora, Colorado, United States
🇺🇸Investigator Site 134, Jackson, Mississippi, United States
🇺🇸Investigator Site 121, Burlington, Vermont, United States
SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis
- Conditions
- Exocrine Pancreatic InsufficiencyCystic Fibrosis
- Interventions
- Drug: Liprotamase Powder for Oral Solution
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT02734810
- Locations
- 🇺🇸
Investigator Site 139, Little Rock, Arkansas, United States
🇺🇸Investigator Site, Orange, California, United States
🇺🇸Investigator Site 114, Aurora, Colorado, United States
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 3
- Registration Number
- NCT02514967
- Locations
- 🇬🇪
Investigator Site 004, Tbilisi, Georgia
🇬🇪Investigator Site 001, Tbilisi, Georgia
🇬🇪Investigator Site 002, Tbilisi, Georgia
SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis
- Conditions
- Exocrine Pancreatic InsufficiencyCystic Fibrosis
- Interventions
- Drug: porcine (pig) PERT
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Anthera Pharmaceuticals
- Target Recruit Count
- 128
- Registration Number
- NCT02279498
- Locations
- 🇺🇸
Investigator Site 123, Long Beach, California, United States
🇺🇸Investigator Site 107, Los Angeles, California, United States
🇺🇸Investigator Site 114, Aurora, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next